Technical Analysis for PHASQ - Phasebio Pharmaceuticals Inc

Grade Last Price % Change Price Change
F 0.0160 8.84% 0.0013
PHASQ closed up 8.84 percent on Friday, February 3, 2023, on 0 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 8.84%
Inside Day Range Contraction 8.84%
Wide Bands Range Expansion 8.84%
Fell Below 20 DMA Bearish 11.89%
Fell Below 50 DMA Bearish 11.89%
180 Bearish Setup Bearish Swing Setup 11.89%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High 7 days ago
Up 5% 7 days ago
Up 3% 7 days ago
Up 10% 7 days ago
Up 2% 7 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Phasebio Pharmaceuticals Inc Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Biopharmaceutical Medication Organic Compounds U.S. Bankruptcy Court Chemical Compounds Alcohols U.S. Bankruptcy Court For The District Of Delaware Cardiovascular Diseases Astrazeneca Cyclopropanes Pulmonary Arterial Hypertension Invasive Procedure Pulmonary Hypertension

Is PHASQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.139
52 Week Low 0.01
Average Volume 513,059
200-Day Moving Average 0.0000
50-Day Moving Average 0.0338
20-Day Moving Average 0.0283
10-Day Moving Average 0.0179
Average True Range 0.0182
RSI 45.05
ADX 29.83
+DI 30.4091
-DI 11.6444
Chandelier Exit (Long, 3 ATRs) 0.0354
Chandelier Exit (Short, 3 ATRs) 0.0646
Upper Bollinger Bands 0.0637
Lower Bollinger Band -0.0071
Percent B (%b) 0.33
BandWidth 250.1767
MACD Line -0.0064
MACD Signal Line -0.0066
MACD Histogram 0.0003
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0180
Resistance 3 (R3) 0.0177 0.0169 0.0176
Resistance 2 (R2) 0.0169 0.0164 0.0170 0.0175
Resistance 1 (R1) 0.0164 0.0161 0.0167 0.0167 0.0174
Pivot Point 0.0156 0.0156 0.0157 0.0157 0.0156
Support 1 (S1) 0.0151 0.0151 0.0154 0.0154 0.0146
Support 2 (S2) 0.0143 0.0148 0.0144 0.0145
Support 3 (S3) 0.0138 0.0143 0.0144
Support 4 (S4) 0.0141